Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma

Journal of Virology

Volumn 72, Issue 1, 1998, Pages 789-795

  Diaz, R M ^a   Eisen, T ^b   Hart, I R ^a   Vile, R G ^c  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b MARIE CURIE RESEARCH INSTITUTE   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOPHENOL MONOOXYGENASE;

ANIMAL CELL; ARTICLE; ENHANCER REGION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; LONG TERMINAL REPEAT; MELANOMA; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; TISSUE SPECIFICITY; VESICULAR STOMATITIS VIRUS; VIRUS TYPING;

EID: 0031984750     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.72.1.789-795.1998     Document Type: Article

References (40)

1. Bentley, N. J., T. Eisen, and R. C. Goding. 1994. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol. Cell. Biol. 14:7996-8006.
2. Bischoff, J., D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. Nye, A. Sampson-Johannes, A. Fattaey, et al. 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376.
3. Boral, A. L., S. A. Okenquist, and J. Lenz. 1989. Identification of the SL3-3 virus enhancer core as a T-lymphoma cell-specific element. J. Virol. 63:76-84.
4. Burns, J. C., T. Friedmann, W. Driever, M. Burrascano, and J. K. Yee. 1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90:8033-8037.
5. Cosset, F.-L., and S. J. Russell. 1996. Targeting retrovirus entry. Gene Ther. 3:946-956.
6. Cosset, F.-L., Y. Takeuchi, J.-L. Battini, R. A. Weiss, and M. K. L. Collins. 1995. High-titer packaging cells producing recombinant retroviruses resistant to human serum. J. Virol. 69:7430-7436.
7. Couture, L. A., C. A. Mullen, and R. A. Morgan. 1944. Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression. Hum. Gene Ther. 5:667-677.
8. Emerman, M., and H. M. Temin. 1984. Genes with promoters in retroviral vectors can be independently suppressed by an epigenic mechanism. Cell 39:459-467.
9. Ferrari, G., G. Salvatori, C. Rossi, G. Cossu, and F. Mavilio. 1995. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum. Gene Ther. 6:733-742.
10. Feuer, G., and H. Fan. 1990. Substitution of murine transthyretin (prealbumin) regulatory sequences into the Moloney murine leukemia virus long terminal repeat yields infectious virus with altered biological properties. J. Virol. 64:6130-6140.
11. Flanagan, J. R., A. M. Krieg, E. E. Max, and A. S. Khan. 1989. Negative control region at the 5′ end of the murine leukemia virus long terminal repeats. Mol. Cell. Biol. 8:739-746.
12. Jolly, D. 1994. Viral vector systems for gene therapy. Cancer Gene Ther. 1:51-64.
13. Majors, J. 1990. Retroviruses, strategies of replication. The structure and function of retroviral long terminal repeats. In R. Swanstrom and P. K. Vogt (ed.), p. 49-92. Springer-Verlag, Berlin, Germany.
14. Markowitz, D., S. Goff, and A. Bank. 1988. Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400-406.
15. Miller, N., and R. G. Vile. 1995. Targeted vectors for gene therapy. FASEB J. 9:190-199.
16. Moolten, F. L. 1994. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Therapy 1:279-287.
17. Ory, D. S., B. A. Neugeboren, and R. C. Mulligan. 1996. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA 93:11400-11406.
18. Palmer, T. D., G. J. Rosman, W. R. A. Osborne, and A. D. Miller. 1991. Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88:1330-1334.
19. Richards, C. A. and B. E. Huber. 1993. Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum. Gene Therapy 4:143-150.
20. Rosen, C. A., W. A. Haseltine, J. Lenz, R. Ruprecht, and M. W. Cloyd. 1985. Tissue selectivity of murine leukemia virus infection is determined by long terminal repeat sequences. J. Virol. 55:862-866.
21. Russell, S. J. 1994. Replicating vectors for cancer therapy: a question of strategy. Semin. Cancer Biol. 5:437-443.
22. Shibata, K., Y. Muraosa, Y. Tomita, H. Tagami, and S. Shibahara. 1992. Identification of a cis-acting element that enhances the pigment cell-specific expression of the human tyrosinase gene. J. Biol. Chem. 267:20584-20588.
23. Short, M. K., S. A. Okenquist, and J. Lenz. 1987. Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J. Virol. 61:1067-1072.
24. Siders, W. M., P. J. Halloran, and R. G. Fenton. 1996. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 56:5638-5646.
25. Vile, R. G. Unpublished observations.
26. Vile, R. G. 1994. Tumour specific gene expression. Semin. Cancer Biol. 5:429-436.
27. Vile, R. G., R. M. Diaz, N. Miller, S. Mitchell, A. Tuszynski, and S. J. Russell. 1995. Tissue specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214:307-313.
28. Vile, R. G., and I. R. Hart. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53:962-967.
29. Vile, R. G., and I. R. Hart. 1993. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53:3860-3864.
30. Vile, R. G., N. Miller, Y. Chernajovsky, and I. R. Hart. 1994. A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1:307-316.
31. Vile, R. G., J. A. Nelson, S. Castleden, H. Chong, and I. R. Hart. 1994. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 54:6228-6234.
32. Vile, R. G., and S. J. Russell. 1995. Retroviruses as vectors. Br. Med. Bull. 51:12-30.
33. Vile, R. G., K. Sunassee, and R. M. Diaz. Strategies for achieving multiple layers of selectivity in gene therapy. Mol. Med. Today, in press.
34. Walther, W., and U. Stein. 1996. Targeted vectors for gene therapy of cancer and retroviral infections. Mol. Biotcchnol. 6:267-286.
35. Whitcomb, J. M., and S. H. Hughes. 1992. Retroviral reverse transcription and integration: progress and problems. Annu. Rev. Cell Biol. 8:275-306.
36. Wilson, C., and M. A. Kay. 1995. Immunomodulation to enhance gene therapy. Nat. Med. 1:890-893.
37. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
38. Yang, Y., G. Trinchieri, and J. M. Wilson. 1995. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat. Med. 1:890-893.
39. Yasumoto, K.-I., K. Yokoyama, K. Shibata, Y. Tomita, and S. Shibahara. 1994. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol. Cell. Biol. 14:8058-8070.
40. Yu, S.-F., T. Von Ruden, P. W. Kantoff, C. Garber, M. Seiberg, U. Ruther, W. French Anderson, E. F. Wagner, and E. Gilboa. 1986. Self inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. USA 83:3194-3198.